key: cord-0261725-grmcvcpj
authors: Ngamsom, B.; Iles, A.; Kamita, M.; Kimani, R.; Rodriguez-Mateos, P.; Mungai, M.; Dyer, C. E.; Walter, C.; Gitaka, J.; Pamme, N.
title: An integrated lab-on-a-chip device for RNA extraction, amplification and CRISPR-Cas12a-assisted detection for COVID-19 screening in resource-limited settings
date: 2022-01-06
journal: nan
DOI: 10.1101/2022.01.06.22268835
sha: 42a27765381ececd8b099e59425847487b779840
doc_id: 261725
cord_uid: grmcvcpj

In response to the ongoing COVID-19 pandemic and disparities of vaccination coverage in low-and middle-income countries, it is vital to adopt a widespread testing and screening programme, combined with contact tracing, to monitor and effectively control the infection dispersion in areas where medical resources are limited. This work presents a lab-on-a-chip platform, namely IFAST-CRISPR, as an affordable, rapid and high-precision molecular diagnostic means for SARS-CoV-2 detection. The herein proposed sample-to-answer platform integrates RNA extraction, amplification and CRISPR-Cas-based detection with lateral flow readout in one device. The microscale dimensions of the device containing immiscible liquids, coupled with the use of silica paramagnetic beads and GuHCl, streamline sample preparation, including RNA concentration, extraction and purification, in 15 min with minimal hands-on steps. By combining RT-LAMP with CRISPR-Cas12 assays targeting the nucleoprotein (N) gene, visual identification of [≥] 470 copies mL-1 genomic SARS-CoV-2 samples was achieved in 45 min, with no cross-reactivity towards HCoV-OC43 nor H1N1. On-chip assays showed the ability to isolate and detect SARS-CoV-2 from 1,000 genome copies mL-1 of replication-deficient viral particles in 1 h. This simple, affordable and integrated platform demonstrated a visual, faster, and yet specificity and sensitivity-comparable alternative to the costly gold-standard RT-PCR assay, requiring only a simple heating source. Further investigations on multiplexing and direct interfacing of the accessible Swan-brand cigarette filter for saliva sample collection could provide a complete work flow for COVID-19 diagnostics from saliva samples suitable for low-resource settings.

Since the first case of coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was reported in Wuhan, China in December 2019, more than 260 million cases and 5.2 million deaths have been reported as of December 7, 2021 (1). Many cases of severe illness and death associated with COVID-19 infections have been prevented in countries where there has been effective implementation of vaccine programmes with ca. 42% of the world population fully vaccinated (data as of December 2021, (2) ). However, disparities in vaccination coverage are an ongoing issue, especially in low-and middle-income countries where, on average, only 6.3% of the population have received one dose. In particular, instances of less than 2% coverage have been reported in more than 20 African countries (3) . Considering the rush for apportionment of the global supply of vaccines between nations, and the inequitable distribution between high and poorincome countries, and emergence of highly transmissible omicron variant (4), increased testing and screening with contact tracing are paramount for infection control in areas where resources are limited.

The gold standard for COVID-19 diagnostics detects the presence of viral RNA from respiratory specimens using real-time reverse transcription-polymerase chain reaction (RT-qPCR) (5) (6) (7) . The analytical limits of detection of RT-qPCR are usually ca. 10 3 viral RNA copies mL -1 with 24-48 h turnaround time (6, 8) . Despite the high sensitivity and specificity for disease diagnosis, the method relies on a highly skilled operator using expensive instrumentation, reducing its applicability for widespread application (6, 9, 10) .

Several point-of-care (POC) RNA detection technologies, requiring no special instruments, employ simultaneous reverse transcription (RT) and isothermal amplification steps such as loopmediated isothermal amplification (LAMP, (11, 12) ) or recombinase polymerase amplification (RPA, (13) ). Although displaying high sensitivity, RT-LAMP and RT-RPA can suffer from nonspecific amplification under isothermal conditions, leading to false-positive results (14, 15) . Other automated commercially available systems such as Cepheid GeneXpert, Roche Cobas and Abbot ID Now offer the ease-of-use aspect with minimal hands-on steps with ≤ 1 h sample-to-result; however, expensive specialized instrumentation is still required for each system (16) .

An alternative to nucleic acid amplification tests, antigen lateral flow assays detect the presence of the virus through specific nucleocapsid proteins of SARS-CoV-2. They require no RNA purification step, and can operate at ambient temperatures with ≤ 30 min turnaround time, making them appealing within POC settings. However, the lack of exponential amplification can hinder the detection limit with a sensitivity of the assays typically being three orders of magnitude lower than the gold standard RT-qPCR (17) .

Clustered regularly interspaced short palindromic repeats (CRISPR)-based diagnostic methods utilize the collateral cleavage activity of bystander nucleic acid probes of RNA-guided CRISPRassociated 12/13 (Cas12/13) nucleases (15, (18) (19) (20) (21) . In combination with RT-LAMP or RT-RPA . CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint isothermal amplification methods, CRISPR-Cas-assisted SARS-CoV-2 detection assays are considered as transformative methods for POC COVID-19 diagnostics (15, (21) (22) (23) (24) (25) . The highly sensitive and specific nature of CRISPR diagnostic methods is attributed to the sequence specificity required for both nucleic acid amplification step and the CRISPR-Cas detection step (15) . Readout of Cas-mediated nucleic acid probe cleavage can either be by fluorescence detection or via lateral flow strip, both of which can be applied for POC purposes (21, 26) . The original DETECTR-based (21) , and SHERLOCKbased (15) detections involved multiple manual steps and operated with already extracted RNA, thereby limiting their applicability for POC use (27) . Although the more recent STOPCovid.v2 assay included a benchtop magnetic-based RNA extraction prior to the one-step CRISPR-Cas12b-assisted RT-LAMP (28) , the assay still requires multi-step manual operation.

Numerous efforts have been made in developing fully integrated, affordable, sensitive, specific, rapid and robust platforms for POC COVID-19 diagnostics exploiting microfluidics or 'lab-on-a-chip' technologies (16, 29) . Such platforms permit viral lysis, RNA extraction, nucleic acid amplification and detection on a single device, allowing more applicable diagnostics within resource-limited settings (27, 30) . Immiscible filtration assisted by surface tension (IFAST) is a microfluidic technique which exploits the surface tension properties of immiscible liquids and microscale dimensions to facilitate side-by-side compartmentation of immiscible liquids, enabling multiple and sequential steps to be performed in one device (31) (32) (33) . The use of suitable functionalized magnetic particles allows rapid isolation and purification of a magnetically responsive analyte from complex matrices (32, (34) (35) (36) (37) (38) (39) .

Here, IFAST and the recent developments in CRISPR-Cas12-based sensing applied to SARS-CoV-2 detection are combined to develop a cost-effective, sensitive, target-specific and fully integrated device for COVID-19 diagnostics, namely 'IFAST-CRISPR', Fig. 1A . The device was designed for streamlined sample preparation to provide rapid isolation and concentration of RNA directly from nasopharyngeal swabs or saliva specimens followed by pivotal CRISPR-Cas-assisted detection with lateral flow readout. The versatility of the developed platform can be implemented for CRISPR-Casbased detections of other pathogens, showing great promise for POC diagnostics particularly in decentralized and resource-limited settings in low-and middle-income countries.

Point-of-care COVID-19 diagnostics is critical to public health; however, current gold-standard RT-PCR methods are labour, equipment, and skill-intensive; resulting in far fewer tests being carried out in low-and middle-income countries such as Kenya. Affordable and highly reliable molecular testing using CRISPR-Cas-based assays with user-friendly sample collection and preparation would expand testing capacities and reduce community transmission in low-resource settings. Here, we describe an affordable sample-to-answer lab-on-a-chip platform which combines a simple sample preparation unit with highly-specific CRISPR-Cas assisted assays in one device, enabling 1 h detection of COVID-19 infections with a sensitivity comparable with gold standard laboratory-based methods. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint

This study was approved by the Mount Kenya University Independent Ethical Review Committee (MKU/IERC/1811). Nasopharyngeal swab and saliva samples were collected from participants with their written informed consent after the nature and possible consequences of the study had been fully explained to them. Devices were cleaned with RNase decontamination solution, followed by rinsing with nucleasefree water, and were left to dry at ambient temperature prior to use. The bottom of the device was sealed with PCR adhesive film.

Tube-based DETECTR assays were performed using RT-LAMP for pre-amplification of genomic SARS-CoV-2 RNA using primers targeting N gene, and LbCas12a for the trans-cleavage assay following the protocol described by Broughton et al. (21) with some modifications. RT-LAMP was conducted at 64 °C for 30 min using 2 μL RNA templates serially diluted (10x) from 4,700 copies μL -1 . RT-LAMP products were identified via agarose gel electrophoresis (1 %w/v agarose, 1xTAE buffer, 80 V, 45 min) and the results analyzed using a molecular imager (Chemidoc XRS+, BioRAD).

LbCas12a-gRNA (RNP) complexes were generated prior to carrying out LbCas12 trans-cleavage assay, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. The capability of the device for CRISPR-Cas12 detection assays was tested on tube-based RNAextraction and RT-LAMP amplicons. MagneSil paramagnetic beads (1 μL) were added into a sample of genomic SARS-CoV-2 RNA diluted in 5 M GuHCl (940 copies mL -1 ) and mixed for 5 min by tube inversion. The RNA-extracted MB were washed with nuclease-free water (100 μL). The washed RNAextracted MB were mixed with RT-LAMP reagent to undergo reaction at 64 °C for 30 min. The amplicons (2 μL) were transferred from the reaction tube into chamber (9) of the chip device which was prefilled with CRISPR-Cas12 assay mix and sealed with PCR adhesive film on the top to prevent contamination. Other chambers were also alternately filled with nuclease-free water (chambers (1), (3), (5), (7)), and mineral oil (chambers (2), (4), (6), (8)). On-chip CRISPR-Cas12 assays were performed at 37 °C for 10 min. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint Combined on-chip RNA extraction, RT-LAMP and CRISPR-Cas12-assisted detection (Steps 1-

On-chip RNA extraction and RT-LAMP were similarly conducted as described above. Extraction was performed for 5 min for samples containing free RNAs, and 15 min for SARS-CoV-2 verification panel samples. After performing RT-LAMP at 64 °C for 30 -45 min, CRISPR-Cas12 reagent mix was added to chamber (9) and MBs from chamber (7) were moved into chamber (9) and the chamber was sealed with PCR adhesive film prior to reaction at 37 °C for 10 min and 2 min for lateral flow readout. was performed in pairs. RNA extraction was carried out using Ribo-Virus RNA extraction kit (Sacace Biotechnologies) and RT-PCR conducted using a TBG Q6000 real time PCR system (TBG Biotechnology).

The IFAST-CRISPR device (Fig. 1B, C) has been designed to combine streamlined IFAST sample preparation for rapid and effective RNA extraction from viral particles, with sensitive and highly is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint specific CRISPR-Cas-associated detection. The design was adapted from our previously reported IFAST RT-LAMP device (2); however, in this instance, the chambers were horizontally aligned for easier magnetic manipulation, multiplexing and automation (Fig. 1C) ; as opposed to the meandering chamber layout in the previous design which was chosen in order to minimise carry-over and device footprint. The gates and interconnecting chambers were of similar dimensions to those of the previous design (Fig. 1B) ; permitting up to 60 min heating at 65 °C with intact immiscible interfaces (2) By passing RNA-bound MBs through two sets of immiscible wash liquids, rapid purification of the magnetic bead-isolated RNA was achieved within a few seconds, thereby protecting the RNA integrity for the subsequent amplification and detection steps.

The following amplification and detection steps were adapted from the reported SARS-CoV-2 DETECTR protocol from Broughton et al. (21) where simultaneous reverse transcription and isothermal amplification were achieved by RT-LAMP, followed by CRISPR-Cas12 detection of target is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ;

DNA amplicons. As well as being affordable and widely accessible, the reported LAMP N gene primer set was also granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration for Mammoth Biosciences (40) . Despite being active at 16 -48 °C, LbCas12a(Cpf1) is commercially available and more accessible than the thermostable AapCas12b exploited in the STOPCovid system (28) . Tube-based CRISPR-Cas assays require the transfer of minute quantities of DNA target from the amplification tube into the CRISPR-Cas detection tube (5, 6) . By including an additional oil chamber after the RT-LAMP chamber on the IFAST-CRISPR device, magnetic manipulation of ampliconsbound on MBs into the CRISPR-Cas detection chamber can easily be achieved, preventing potential contamination introduced by amplicon transfer by pipetting. 

Validation of the CRISPR-Cas12a-based assays for SARS-CoV-2 detection was first carried out in tubes on a series of ten-fold dilutions of genomic RNA with initial concentration of 4700 copies μL -1 . Utilising primers targeting N gene, positive amplifications were observed from 4.7 copies of genomic RNA after 30 min (Fig. 2a, gel electrophoresis) ; a much higher sensitivity compared with the pH-dependent colorimetric RT-LAMP assay reported in our previous study where ≥ 470 genome copies were amplified at the same reaction time (33) . Visual signals observed from 10 min CRISPR-Cas12 detection in the following step confirmed the sensitivity of the assay to detect down to 4.7 genome copies ( Fig. 2A, lateral flow strips) . The specificity of the gRNA in the CRISPR-Cas12 assay only towards SARS-CoV-2 with no cross-reactivity with the related HCoV-OC43 and influenza A H1N1 is demonstrated in Fig. 2B . Although positive amplifications were detected with correct pairing between RNAs and their respective primers (Fig. 2B, gel electrophoresis) , a test line only appeared on the strip from the SARS-CoV-2 sample as a result of Cas12 trans-cleavage activity following hybridization of the gRNA-targeted DNA sequence.

The CRISPR-Cas-assisted assay was further tested with RNA extracted from nasopharyngeal swab samples (Fig. 2C) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; the RT-qPCR result and confirmed its superior sensitivity over the antigen lateral flow assay where negative result was observed.

In order to apply the IFAST-CRISPR device for SARS-CoV-2 detection, individual steps onchip were systematically evaluated. Utilizing silica paramagnetic beads combined with guanidinium salt, genomic SARS-CoV-2 was extracted and purified through the immiscible liquids, and finally underwent RT-LAMP on chip. The amplification products were subsequently detected via tube-based CRISPR-Cas12 assay. Verification of target DNA amplicons successfully generated from magneticallyisolated RNA from initial samples containing ≥ 470 genome copies mL -1 is demonstrated in Fig. 3A .

The feasibility of performing a CRISPR-Cas12a assay for the specific detection of target DNA on-chip was next investigated. The corresponding readout signals from negative and positive samples suggested the viability of the IFAST-CRISPR device as a reactor for the trans-cleavage activity of Cas12a to detect target amplicons (Fig. 3B ).

The performance of the IFAST-CRISPR device was next examined on the combined workflow for extraction, RT-LAMP and CRISPR-Cas12a detection of samples containing genomic RNA (Fig. 3c top). Negative sample containing HCoV-OC43 and H1N1 RNAs showed only a control line on the lateral flow test strip, whilst test lines were present from positive samples containing HCoV-OC43, H1N1 and ≥470 copies mL -1 SARS-CoV-2 RNAs. These results not only validated the successful integration of consecutive steps on-chip, but they also confirmed the assay specificity as previously described in Fig. 2b . The assay performance of the IFAST-CRISPR device was further evaluated using replication-deficient SARS-CoV-2 viral particle samples (SeraCare AccuPlex SARS-CoV-2 Verification Panel). By mixing the viral sample with silica paramagnetic beads and 5 M GuHCl, lysis of viral particles and binding of SARS-CoV-2 RNA to magnetic beads were accomplished simultaneously (Fig. S2 ). Translating the same process onto the IFAST-CRISPR device, coupled with rapid washing through minute quantities of immiscible liquids, demonstrated that RNA can be magnetically isolated and detected from contrived viral samples containing 1,000 genome copies mL -1 in 15 min (Fig. 3Cbottom) . RT-LAMP DNA amplicons generated from the magnetically-isolated RNA, verified by gel electrophoresis, confirmed the efficient on-chip purification process in eliminating possible RT-LAMP assay inhibitor crossing over from the sample chamber. Finally, recognition of target DNA sequences that had been magnetically transported to the CRISPR-Cas12a detection chamber was performed. This was achieved by using the Cas12a gRNA initiated collateral cleavage of ssDNA reporter, leading to a test line on the lateral flow strip, similar to the tube-based assay for positive control of free SARS-CoV-2 RNA. This simple, and yet complete on-chip workflow has already shown a similar level of detection as the gold standard RT-qPCR (1,000 copies mL -1 ) and has the potential to be further optimized. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint

Another aim of the present study was to replace the uncomfortable nasopharyngeal (NP) or oropharyngeal (OP) swabbing with saliva sampling using a cigarette-type filter. Although NP and OP swab specimens have been considered reliable and are most often used for COVID-19 diagnostics (7), (6) , acquiring an NP/OP swab can be unpleasant, and can initiate coughing leading to increasing risk of nosocomial spread of respiratory viruses (41) , as well as in suboptimal specimens being collected dependent upon the experience of the collector. Being inexpensive and easy to access, Swan brand cigarette filters were investigated as potential substrate for saliva collection for COVID-19 screening in low-resource settings. The feasibility of introducing a viral sample from a Swan cigarette filter for the IFAST-CRISPR device was examined using genomic SARS-CoV-2 RNA (Fig. S2 and Fig. 4A ).

No adverse effect from the filters was observed either on RT-LAMP or CRISPR-Cas12a assays performed on-chip. Additionally, Swan brand filters were tested with dilutions of a SARS-CoV-2 positive nasopharyngeal swab specimens. After immersing a filter in 1 mL of each dilution, the liquid retained within the filters was extracted and subjected to RT-qPCR. Ct values obtained from the samples retained within the filters compared favourably to those of the initial samples without filters, indicating neither RT-qPCR assay inhibition nor compromised RNA integrity by the use of Swan filters (Fig. 4b) .

These proof-of-concept methodological approaches verify the potential use of Swan filters for saliva collection, which can be directly interfaced with the IFAST-CRISPR device.

The present manuscript demonstrated the manual operation of an IFAST-CRISPR device, for use as a molecular COVID-19 diagnostic tool, by a semi-trained operator in resource-limited laboratories in sub-Saharan Africa, e.g., Kenya. The device has been designed to operate with already available laboratory facilities such as incubators for heating and shakers for RNA extraction. Although presently being fabricated by CNC milling, the thermoplastic polymethyl methacrylate devices can be mass produced by injection moulding. The total cost of a device including materials and reagents is currently around 8 USD (Table S1 , Supporting Information).

We have demonstrated a microfluidic platform which integrated all essential steps necessary for SARS-CoV-2 detection: as an affordable COVID-19 molecular diagnostic device with similar sensitivity and specificity to the gold standard RT-qPCR tests. The platform required only a basic heating source such as simple incubators or hot plates which are usually available in most laboratories in low-resource settings, without the need for costly or specialized instruments. This simple, and yet highly versatile platform can potentially be applied not only for COVID-19 screening, but also for other pathogenic infections. This allows affordable, sensitive, target-specific, quick turnaround nucleic amplification tests (NAATs) to be achieved where rapid and precise diagnostic tools are needed for infection containment as well as for timely treatment. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint Samples collected using cigarette filters: tube-based assays; 1 = nuclease-free water; 2 = initial sample containing 94 genome copies; 3 = sample extracted from cigarette filter immersed in 47 copies μL -1 of RNA sample. On-chip assays; 4, 5 = magnetic bead-extracted RNA extracted from cigarette filters with initial concentration of 4700 copies mL -1 . (B) Ct values of samples before and after being subjected to Swan filters from various dilutions of a SARS-CoV-2 positive saliva samples (n = 1).

. CC-BY-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.06.22268835 doi: medRxiv preprint

Our World in Data (2021) Coronavirus (COVID-19) vaccinations

Africa CDC vaccine dashoard

Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic

Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes

Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa

Mild or Moderate Covid-19

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Current diagnostic tools for coronaviruses-From laboratory diagnosis to POC diagnosis for COVID-19

Considerations for diagnostic COVID-19 tests

Loop-mediated isothermal amplification of DNA

SARS-CoV-2 detection using isothermal amplification and a rapid, inexpensive protocol for sample inactivation and purification

DNA detection using recombination proteins

LAMP Diagnostics at the Point-of-Care: Emerging Trends and Perspectives for the Developer Community

Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA

A critical review of point-of-care diagnostic technologies to combat viral pandemics

WHO (2020) Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays

CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity

Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6

Programmed DNA destruction by miniature CRISPR-Cas14 enzymes

CRISPR-Cas12-based detection of SARS-CoV-2

SARS-CoV-2 detection with CRISPR diagnostics

Ultra-sensitive and high-throughput CRISPR-p owered COVID-19 diagnosis

Development and evaluation of a rapid CRISPR-based diagnostic for COVID-19

opvCRISPR: One-pot visual RT-LAMP-CRISPR platform for SARS-cov-2 detection

Point-of-care testing for COVID-19 using SHERLOCK diagnostics

Point-of-care CRISPR-Cas-assisted SARS-CoV-2 detection in an automated and portable droplet magnetofluidic device

Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing

Detection of COVID-19: A review of the current literature and future perspectives

Sample-to-answer COVID-19 nucleic acid testing using a low-cost centrifugal microfluidic platform with bead-based signal enhancement and smartphone read-out

Purification of cell subpopulations via immiscible filtration assisted by surface tension (IFAST)

On-site genetic analysis for species identification using lab-on-a-chip

A lab-on-a-chip platform for integrated extraction and detection of SARS-CoV-2 RNA in resource-limited settings

Streamlining gene expression analysis: integration of co-culture and mRNA purification

Facile and rapid DNA extraction and purification from food matrices using IFAST (immiscible filtration assisted by surface tension)

Automated operation of immiscible filtration assisted by surface tension (IFAST) arrays for streamlined analyte isolation

Sample introduction interface for on-chip nucleic acid-based analysis of Helicobacter pylori from stool samples

A Microfluidic Device for Rapid Screening of E-coli O157:H7 Based on IFAST and ATP Bioluminescence Assay for Water Analysis

Rapid detection of Group B Streptococcus (GBS) from artificial urine samples based on IFAST and ATP bioluminescence assay: from development to practical challenges during protocol testing in Kenya

A protocol for rapid detection of the 2019 novel coronavirus SARS-CoV-2 using CRISPR diagnostics: SARS-CoV-2 DETECTR

Review of aerosol transmission of influenza A virus

The study was financially supported by the Newton-Utafiti Fund Kenya Country Prize 2020.